[Medical treatment of pulmonary hypertension: what's new?].
Pulmonary hypertension (PH) is a chronic progressive disease of the pulmonary circulation of multifactorial causes. The current diagnostic classification of PH distinguishes five main groups, which have as a common feature an increased pulmonary arterial pressure and pulmonary resistance. The classification differentiates pulmonary arterial hypertension (PAH), PH due to left heart disease, PH in lung diseases and/or hypoxia, chronic thromboembolic pulmonary hypertension (CTEPH), and PH with unclear/multifactorial mechanisms. Recent advances in basic research with the approval of new drugs and the establishment of therapeutic strategies, mainly in PAH and CTEPH, require a differentiated view of the disease, a careful diagnosis and initiation of therapy, and regular follow-ups. In this article, we provide an overview of the complex drug therapy currently available for PAH patients.
Abteilung für Allgemeine Pneumologie, Lungenzentrum, Kerckhoff-Klinik Bad Nauheim, Kerckhoff-Klinik GmbH, Benekestr. 2-8, 61231, Bad Nauheim, Deutschland.
M J
MJ
Richter
H
H
Gall
K
K
Tello
N
N
Sommer
W
W
Seeger
F
F
Grimminger
H A
HA
Ghofrani
D000959:Antihypertensive Agents / Q000008:administration & dosage*; D065128:Endothelin Receptor Antagonists / Q000008:administration & dosage*; D019317:Evidence-Based Medicine; D006162:Guanylate Cyclase; D006801:Humans; D006976:Hypertension, Pulmonary / Q000175:diagnosis / Q000188:drug therapy*; D058986:Phosphodiesterase 5 Inhibitors / Q000008:administration & dosage*; D011453:Prostaglandins / Q000008:administration & dosage*; D018160:Receptors, Cytoplasmic and Nuclear / Q000819:agonists*; D000071756:Soluble Guanylyl Cyclase; D016896:Treatment Outcome
D000959:Antihypertensive Agents; D065128:Endothelin Receptor Antagonists; D058986:Phosphodiesterase 5 Inhibitors; D011453:Prostaglandins; D018160:Receptors, Cytoplasmic and Nuclear; D006162:Guanylate Cyclase; D000071756:Soluble Guanylyl Cyclase